Természetes ölösejt aktivitásának változása felületes hólyagtumoros betegek intravesicalis BCG terápiája során.

L. Samodai, K. Dankó

Research output: Article

Abstract

Alteration of natural killer (NK) activity from the peripherial blood was examined in the patients with superficial bladder cancer during two years between 1989-1991. The natural killer cell activity in patients with superficial bladder cancer was significantly depressed that activity was found in normal controls (P less than 0.01). 23 patients received intravesical BCG immuntherapy and NK activity was detected in the same patients 72 times in different period during the therapy. The authors decided that the activity of NK cells alters in BCG therapy. Increase of NK cells activity in the most common way of this alteration but many different type of this change is possible. The lower dose BCG (120 mg) often induce augmentation of NK activity but high dose BCG (200 mg) more frequently caused depressed activity of NK cells. The authors didn't find direct connection between therapy effect and NK activity but they found significantly less NK activity (P less than 0.03) in the patients who are in relapse. According to their opinions the role of natural killer cells in the antitumor effect of BCG can not be excluded. They recommended more immunological investigations to clear up the anticancer effect of BCG immuntherapy.

Original languageHungarian
Pages (from-to)2283-2286, 2291
JournalOrvosi Hetilap
Volume133
Issue number36
Publication statusPublished - szept. 6 1992

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Natural Killer Cells
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{98b85ac596f9462195ffc463d59c4949,
title = "Term{\'e}szetes {\"o}l{\"o}sejt aktivit{\'a}s{\'a}nak v{\'a}ltoz{\'a}sa fel{\"u}letes h{\'o}lyagtumoros betegek intravesicalis BCG ter{\'a}pi{\'a}ja sor{\'a}n.",
abstract = "Alteration of natural killer (NK) activity from the peripherial blood was examined in the patients with superficial bladder cancer during two years between 1989-1991. The natural killer cell activity in patients with superficial bladder cancer was significantly depressed that activity was found in normal controls (P less than 0.01). 23 patients received intravesical BCG immuntherapy and NK activity was detected in the same patients 72 times in different period during the therapy. The authors decided that the activity of NK cells alters in BCG therapy. Increase of NK cells activity in the most common way of this alteration but many different type of this change is possible. The lower dose BCG (120 mg) often induce augmentation of NK activity but high dose BCG (200 mg) more frequently caused depressed activity of NK cells. The authors didn't find direct connection between therapy effect and NK activity but they found significantly less NK activity (P less than 0.03) in the patients who are in relapse. According to their opinions the role of natural killer cells in the antitumor effect of BCG can not be excluded. They recommended more immunological investigations to clear up the anticancer effect of BCG immuntherapy.",
author = "L. Samodai and K. Dank{\'o}",
year = "1992",
month = "9",
day = "6",
language = "Hungarian",
volume = "133",
pages = "2283--2286, 2291",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Természetes ölösejt aktivitásának változása felületes hólyagtumoros betegek intravesicalis BCG terápiája során.

AU - Samodai, L.

AU - Dankó, K.

PY - 1992/9/6

Y1 - 1992/9/6

N2 - Alteration of natural killer (NK) activity from the peripherial blood was examined in the patients with superficial bladder cancer during two years between 1989-1991. The natural killer cell activity in patients with superficial bladder cancer was significantly depressed that activity was found in normal controls (P less than 0.01). 23 patients received intravesical BCG immuntherapy and NK activity was detected in the same patients 72 times in different period during the therapy. The authors decided that the activity of NK cells alters in BCG therapy. Increase of NK cells activity in the most common way of this alteration but many different type of this change is possible. The lower dose BCG (120 mg) often induce augmentation of NK activity but high dose BCG (200 mg) more frequently caused depressed activity of NK cells. The authors didn't find direct connection between therapy effect and NK activity but they found significantly less NK activity (P less than 0.03) in the patients who are in relapse. According to their opinions the role of natural killer cells in the antitumor effect of BCG can not be excluded. They recommended more immunological investigations to clear up the anticancer effect of BCG immuntherapy.

AB - Alteration of natural killer (NK) activity from the peripherial blood was examined in the patients with superficial bladder cancer during two years between 1989-1991. The natural killer cell activity in patients with superficial bladder cancer was significantly depressed that activity was found in normal controls (P less than 0.01). 23 patients received intravesical BCG immuntherapy and NK activity was detected in the same patients 72 times in different period during the therapy. The authors decided that the activity of NK cells alters in BCG therapy. Increase of NK cells activity in the most common way of this alteration but many different type of this change is possible. The lower dose BCG (120 mg) often induce augmentation of NK activity but high dose BCG (200 mg) more frequently caused depressed activity of NK cells. The authors didn't find direct connection between therapy effect and NK activity but they found significantly less NK activity (P less than 0.03) in the patients who are in relapse. According to their opinions the role of natural killer cells in the antitumor effect of BCG can not be excluded. They recommended more immunological investigations to clear up the anticancer effect of BCG immuntherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027113879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027113879&partnerID=8YFLogxK

M3 - Article

C2 - 1408062

AN - SCOPUS:0027113879

VL - 133

SP - 2283-2286, 2291

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -